Financial Results Of Fiscal Year Ended June 2021
Financial Results ofFiscal Year ended June 2021August 13, 2021(Securities code: 7747 First Section of the Tokyo Stock Exchange,First Section of the Nagoya Stock Exchange)
All Rights Reserved. Copyright 2021 ASAHI INTECC CO., LTD.Contents1. Summary of Consolidated Financial forFYE June 20212. Earnings Forecast for FYE June 20221
2All Rights Reserved. Copyright 2021 ASAHI INTECC CO., LTD.FYE June 2021 Main Points-1Revenue 61,507 Mil. Yen Year-on-year 8.8% Revenue increased mainly in overseas markets in the medical division,despite the lingering impact of COVID-19 Medical Division Despite the impact of COVID-19, revenue increased due to the trend of recovery in demand JapanOverseas Decrease in the number of cases since April 2020 compared to normal due to the impact of COVID-19 Increase year-on-year in number of sales volume of PTCA GW Increase in both peripheral vascular and neurovascular field in the non-cardiovascular fields Reimbursement price reduction in October 2019 and April 2020 (-285 Mil. yen) Decrease year-on-year in the number of cases mainly in EU, Middle East and Asia due to the impact of COVID-19 Increase in PTCA GW and penetration catheters due to strengthening sales promotion in Chinese and US market In Non-Cardiovascular segment , increase in Neurovascular field in US, Chinese, and Europe and Middle Easternmarket Influence of the exchange rate fluctuation ( 486 Mil. yen)Device Division Decrease in Medical Components business due to the impact of COVID-19 In Medical Components business, decrease in Abdominal vascular catheter components and Cardiovascular examinationcatheter components for US market In Industrial Components business, increase in business related to the domestic construction, home appliance and automobilemarket, and the overseas leisure market
3All Rights Reserved. Copyright 2021 ASAHI INTECC CO., LTD.FYE June 2021 Main Points-2Although SGA such as R & D expenses increased due to continuous upfrontinvestment, operating income increased slightly Gross profit : 41,468 Mil. Yen YoY 9.0% Increase in gross profit due to increase in revenue and gross profit margin Operating income : 12,795 Mil. Yen YoY 2.8% Increase in R&D expenses (YoY 945 Mil. Yen, Ratio of Revenue 12.2%)Increase in operating expenses due to direct salesIncrease in IT expenses due to recovering from network issues caused by unauthorized accessand strengthening IT systemsAccrual of M&A handling costs Ordinary income : 13,196 Mil. Yen YoY 7.2% Increase in currency exchange gain (YoY 535 Mil. Yen) Net income attributable to parent company shareholders :9,984 Mil. Yen YoY 8.8% Decrease in subsidy income (YoY -959 Mil. Yen)Exchange rate (Unit: JPY)FYE June 2021FYE June 2020US .49
4All Rights Reserved.Copyright 2021 ASAHI INTECC CO.,LTD.HighlightsFYE June 2020Amount(Mil. Yen)FYE June 2021InitialPlanAugust14th 2020Ratio(%)Compared to initialplanYoYAmount(Mil. Yen)Ratio(%)Changes(Mil. Yen)Changes(%)Amount(Mil. Yen)Changes(%)56,546 100.060,54261,507 100.0 4,961 8.8 965 1.6Gross profit38,03867.340,67041,46867.4 3,429 9.0 797 2.0Operatingincome12,44522.012,61912,79520.8 349 2.8 175 1.4Ordinaryincome12,31021.812,49613,19621.5 885 7.2 700 5.6Net incomeattributable toparent companyshareholders9,17816.29,1939,98416.2 805-35.28yen38.25yen- 3.00yenRevenueEPS35.25yen 8.8 8.5 791 8.6 2.97yen 8.4
5All Rights Reserved. Copyright 2021 ASAHI INTECC CO., LTD.Net Revenue by SegmentFYE June 2020Amount(Mil. Yen)FYE June 2021Ratio(%)Amount(Mil. Yen)Ratio(%)Changes(Mil. Yen)Changes(%)Medical47,85584.653,06886.3 5,213 10.9Device8,69015.48,43813.7-252-2.9Total amount56,546100.061,507100.0 4,961 8.8Medicalfield51,93191.856,72592.2 4,793 9.2Industrialfield4,6148.24,7827.8 167 3.6(Reference)
6All Rights Reserved. Copyright 2021 ASAHI INTECC CO., LTD.Operating Income by SegmentFYE June 2020Amount(Mil. Yen)FYE June 2021Ratio(%)Amount(Mil. Yen)Ratio(%)Changes(Mil. Yen)Changes(%)Medical12,60879.413,70080.4 1,091 8.7Device3,27820.63,34919.6 71 2.2Subtotal15,886100.017,049100.0 1,163 7.3Erasing &Head Quarters-3,441―-4,254―-813-23.6Total amount12,455―12,795― 349 2.8(Reference)Device DivisionSegment Revenue4,449―5,665― 1,215 27.3
7All Rights Reserved. Copyright 2021 ASAHI INTECC CO., LTD.Earnings Performance by Segment( Mil. Yen )【 Revenue 】( Mil. Yen )【 Operating Income 3,000FYE June 017,000-3,00012,455FYE June 2021-5,000FYE June 2020FYE June 2021
8All Rights Reserved. Copyright 2021 ASAHI INTECC CO., LTD.Attribution Analysis of Operating Income – 1(Exchange Rate Fluctuations Included)( Mil. Yen )17,000Positive effect ofincreased revenue15,0003,34513,000Negative effectof increasedexpenses other thanR&D 84Positive effectof increasedgross profit rate-2,135Negative effectof increasedR&D expenses12,795-94512,445Increase in SGA: -3,080（SGA：Selling, general and administrative expenses)11,000 9,000Increase in R&D expensesIncrease in operating expenses due to direct salesIncrease in IT expensesM&A related expenses Medical Division : Increase due to the strengthening the sales promotionactivities in overseas market despite the impact of COVID-19 Device Division : Decrease due to the impact of COVID-197,000FYE June 2021 ： US 106.58 EURO 127.06 CNY 16.12 BAHT 3.45FYE June 2020 ： US 108.19 EURO 119.62 CNY 15.38 BAHT 3.495,000FYE June 2020FYE June 2021Operating IncomeOperating Income
9All Rights Reserved. Copyright 2021 ASAHI INTECC CO., LTD.Attribution Analysis of Operating Income – 2(Exchange Rate Fluctuations Excluded)( Mil. Yen )Positive effectof increasedrevenue17,000-19815,000Currencyexchange ratefluctuations13,00012,44511,000 629 3,028Negative effectof increasedgross profit rate-2,147-962Negative effect ofIncreased expensesother thanNegative effect ofR&DIncreasedR&D expenses12,795Increase in SGA: -3,1109,0007,000FYE June 2021 ： US 106.58 EURO 127.06 CNY 16.12 BAHT 3.45FYE June 2020 ： US 108.19 EURO 119.62 CNY 15.45 BAHT 3.495,000FYE June 2020Operating IncomeFYE June 2021Operating Income
All Rights Reserved. Copyright 2021 ASAHI INTECC CO., LTD.10Per Segment by Medical Division(by Geography - 1)【Revenue (YoY) 】(Mil. Yen)55,000 Japan: Increase in volume despite continued impact of COVID-19 and influence ofreimbursement price reduction (-285 783 PTCA GW: Although the volume increased, the amount decreased slightly due to the influence of thereimbursement price reduction Non-cardiovascular field: Strong sales of peripheral vascular and neurovascular productsOther6,308 Overseas: Increase in revenue due to strengthening sales promotion activities and thepromotion of direct sales despite decrease in the number of cases due to the impact ofChinaCOVID-19 US 35,00030,00010,143Europe/11,102 MiddleEast9,67911,311 US25,00020,00015,00010,00014,73814,575 Japan5,000PTCA GW: Despite the impact of COVID-19, increase in number associated with promotion of direct salesNon-cardiovascular field : Increase due to the switch to the direct sales of neurovascular productsin the second half of the yearOEM: Increase in supply of FFR components for Boston Scientific (US) Europe/Middle East Western Europe increased while Eastern Europe/Russia and Middle East decreasedWestern Europe: Increase due to the promotion of direct sales in France and Germany, etc.Middle East: Impact of COVID-19, etc.Eastern Europe/Russia : Carry-over to next fiscal year China PTCA GW / Penetration Catheter :Increase significantly due to strengthening sales promotion activitiesNon-cardiovascular segment: Strong sales of Neurovascular products Other PTCA GW / Penetration Catheter : Increase due to the promotion of direct sales in Korea despite the theimpact of COVID-19【Operating Income】0FYE June2020FYE June2021 Operating income increased with sales increase despite increase in R&D expenses
11All Rights Reserved. Copyright 2021 ASAHI INTECC CO., LTD.Per Segment by Medical Division(by Geography - 2)(Mil. Yen)YoYFYE June 2020FYE June 2021ChangesChanges (%)USD108.19106.58-1.61-1.5EURO119.62127.06 7.44 6.2CNY15.3816.12 0.74 4.847,85553,068 5,213 10.9Japan14,73814,575-163-1.1Overseas33,11638,493 5,377 16.2US9,67911,311 1,631 16.910,14311,102 958 9.5China7,7839,771 1,987 25.5Other5,5096,308 799 14.512,60813,700 1,091 8.7Exchange rate(Yen)Total RevenueEurope/Middle EastOperating income
All Rights Reserved. Copyright 2021 ASAHI INTECC CO., LTD.12Per Segment by Medical Division(by Treatment - 1)【Revenue (YoY) 】Cardiovascular( Mil. Yen 926,52320,000 Japan: : Increase in volume despite continued impact of COVID-19 and influence ofreimbursement price reduction(Japan) Overseas: Increase in revenue due to strengthening sales promotion activities and thepromotion of direct sales despite decrease in the number of cases due to the impact of(Overseas)COVID-19Noncardiovascular PTCA GW: Increase mainly in Chinese and US market despite impact of COVID-19(Japan)US: Despite the impact of COVID-19, increase in number due to thepromotion of direct salesChinese: Increase significantly due to strengthening sales promotionactivitiesEurope/Middle East: Western Europe increased while EasternEurope/Russia and Middle East decreasedWestern Europe: Increase due to the promotion of direct sales in(Overseas)France and Germany, etc.Middle East: Impact of COVID-19, etc.Eastern Europe/Russia : Carry-over to next fiscal yearOthers:Increase due to direct sales in South KoreaCardio Penetration Catheter: Increase in US and China 010,0005,0008,6518,423(Japan) Japan: Strong sales of peripheral vascular and neurovascular product Overseas: Neurovascular field:Increase due to the switch to the direct sales of neurovascular products in USStrong sales in ChinaOEM0FYE June 2020 FYE June 2021 Japan: Increase in business of wires for Peripheral vascular, etc.Overseas: Increase in supply of FFR components for Boston Scientific (US)
13All Rights Reserved. Copyright 2021 ASAHI INTECC CO., LTD.Per Segment by Medical Division(by Treatment - 2)(Mil. Yen)YoYFYE June 2020FYE June 19.62127.06 7.44 6.2CNY15.3816.12 0.74 4.847,85553,068 5,213 10.9Japan14,73814,575-163-1.1Overseas33,11638,493 5,377 16.2Cardiovascular35,17538,903 3,728 10.68,6518,423-227-2.626,52330,479 3,955 14.9Non-cardiovascular8,2599,109 850 10.3Japan3,6523,561-91-2.5Overseas4,6065,548 942 20.54,4205,055 634 14.4Japan2,4342,589 155 6.4Overseas1,9862,465 478 24.1Exchange rate (Yen)Total RevenueJapanOverseasOEM
14All Rights Reserved. Copyright 2021 ASAHI INTECC CO., LTD.Per Segment by Device Division - 1( Mil. Yen )9,000【Revenue (YoY) 】8,690Decreased in medical components business due to the lingeringeffects of the impact of COVID-19 although strong sales of industrialcomponents Components6,000(Japan)5,0001,160Japan: Decrease in endoscope components, etc.Overseas: Decrease in Abdominal vascular catheter componentsand Cardiovascular examination catheter components for USIndustrial nents2,0000 1,1084,0001,000Medical Components2,2392,443FYE June 2020 FYE June 2021 Japan: Revenue increased due to increase in business related toconstruction, home appliance and automobile market despitedecrease in business related to office automation market Overseas: Revenue decreased due to decrease in business relatedto automobile and office automation market despite increase inbusiness related to leisure market(Japan)【Operating Income】 Operating income increased with intersegment transactionsincrease despite decrease in external revenue
15All Rights Reserved. Copyright 2021 ASAHI INTECC CO., LTD.Per Segment by Device Division - 2FYE June2020FYE June2021(Mil. Yen)YoYChangesChanges(%)Exchange rate (Yen) USD108.19106.58-1.61-1.5Total Revenue8,6908,438-252-2.9Japan3,3993,552 152 144,782 167 3.62,2392,3752,4432,338 203-36 9.1-1.5%Operating income3,2783,349 71 2.2%(Reference)Segment Revenue4,4495,665Medical ComponentsIndustrial ComponentsJapanOverseas 1,215 27.3
16All Rights Reserved. Copyright 2021 ASAHI INTECC CO., LTD.Reference: P/LFYE June 2020Amount(Mil. Yen)Ratio(%)FYE June 2021Amount(Mil. Yen)Ratio(%)Changes(Mil. Yen)Main comparison factors・Increase due strengthening sales promotion inChina and US56,546100.061,507100.0 4,96118,50732.720,03932.6 1,531Gross profit38,03867.341,46867.4 3,429・Increase due to increase in revenueSGA25,59245.328,67346.6 3,080・Increase in R&D expenses and personnel expenses12,44522.012,79520.8 349Non-operating income1410.36661.1 524Non-operating expense2770.52650.4-1112,31021.813,19621.5 885Extraordinary gain9591.71140.2-845・Decrease in subsidy incomeExtraordinary loss6121.11770.3-434・Decrease in Operating compensation9,17816.29,98416.2 805RevenueCost of salesOperating incomeOrdinary incomeNet income attributable toparent companyshareholdersComprehensive income9,25116.410,75317.5 1,501・Increase in currency exchange gain・Increase in valuation difference on available-forsale securities: 375・Increase in foreign currency translationadjustment: 129
17All Rights Reserved. Copyright 2021 ASAHI INTECC CO., LTD.Reference: B/SFYE June 2020Amount(Mil. Yen)Currentassets47,793FYE June 2021Ratio(%)Amount(Mil. Yen)51.061,132Ratio(%)53.0Changes(Mil. Yen) 13,339AssetsFixedAssetsTotal assetsCurrentLiabilities45,93549.054,29447.0 8,35893,729100.0115,427100.0 21,69712,78613.614,67212.7 1,8868,9689.67,8166.8-1,15121,75423.222,48819.5 734LiabilitiesFixedliabilitiesTotal liabilitiesTotal net assetsTotal liabilities &net assets71,97593,72976.8100.092,938115,42780.5100.0 20,963 21,697Main comparison factorsReceivable-trade:Cash and deposit: 2,957 2,804Tangible fixed assets:Investments and other assets:Intangible fixed assets: 5,404 1,955 998Short-term debt:Provision for bonuses :Accrued corporate tax, etc.: 1,605 662-232Long-term debt:-1,474Capital stock and capitalsurplusRetained earnings: 12,465 7,688
18All Rights Reserved. Copyright 2021 ASAHI INTECC CO., LTD.Reference: C/FAcquisition of tangible fixed assets:-9,906Expenditure for acquisition of shares in subsidiariesresulting in change in scope of consolidation: -3,690Acquisition of intangible fixed assets:-1,582( Mil. Yen )30,000Proceeds from exercising of subscriptionrights to stock option: 12,447Cash dividends paid: 0Effect of exchangerate changes15,00010,000Income before income taxes and others:Depreciation and amortization:Increase in payable-trade :Income tax paid:Increase in receivable-trade :Increase in inventories :5,000 13,132 4,819-199-3,827-2,754-2,3870FYE June 2020Cash andCash inancingActivitiesOtherFYE June 2021Cash andCash Equivalents
19All Rights Reserved.Copyright 2021 ASAHI INTECC CO.,LTD.R&D ExpensesIncrease in R&D expenses for new projects(Mil. Yen)14.0%R&D Expenses12.2%12,000Ratio of Revenue to R&D 64.0%2,0002.0%00.0%FYE June2016FYE June2017FYE June2018FYE June2019FYE June2020FYE June2021
20All Rights Reserved.Copyright 2021 ASAHI INTECC CO.,LTD.Results and Plan for Equipment InstallationExpansion of development bases for the purpose of expanding core technology researchPlan to implement expansion of overseas factory bases to increase production in the future( Mil. Yen )FYE June 2019 FYE June 2020 FYE June 2021(Results)(Results)(Results)Main investment matterConstruction of New Building at Seto factory30,000Establishment of Tohoku R&D Center2,154157294249Expansion of Osaka R&D Center3,710Land and Building (New Thai Medical factory)25,000Expansion of Thai Medical factory20,0001,478Construction of First Cebu Medical factory302Construction of Second Cebu Medical factory478Land and Building(New Cebu Device factory )15,00010,000EquipmentInvestmentIntroduction of core information system(SAP)(Start operation in July 361Depreciation andAmortization9,7028,1835,1695,0003,8362,2870FYE June20162,552FYE June20172,886FYE June20183,460FYE June20194,198FYE June20204,819FYE June2021
All Rights Reserved.Copyright 2020 ASAHI INTECC CO.,LTD.Contents1. Summary of Consolidated Financial forFYE June 20212. Earnings Forecast for FYE June 202221
22All Rights Reserved.Copyright 2020 ASAHI INTECC CO.,LTD.Vision for FYE June 2022Significant increase especially in overseas sales of Medical DivisionOperating income is expected to increase despite an increase in SGA to support sustainable growth Revenue is expected to increase to 75,296 Mil. Yen ( 22.4% YoY) due to increase in MedicalDivision in all regions COVID-19 is assumed to recover in all except a few regions Cardiovascular field: Sales increase due to the expansion of market share by strengthening sales promotionIncreasingand direct sales in addition to the return of the number of cases for PTCA GW and penetration catheterfactors Non-cardiovascular field: Sales increase due to enhancement by new product launches mainly in US and EUfor peripheral vascular products. Expect to increase market share for neurovascular products in all regions Increase in sales revenue due to M&A 3,169 Mil. YenDecreasing factorsImpact of reimbursement price reduction (-242 Mil. Yen) Although SGA will increase due to operating expenses and amortization of goodwill, operatingincome is expected to increase due to increased revenue Decrease in Gross profit ratio due to increase in Fixed cost (depreciation cost)Assumed Exchange Rate Operating income 14,510 Mil. Yen (YoY 13.4%) Increase in R&D expenses (8,904 Mil. Yen, revenue ratio 11.8 %)Increase in expenses due to strengthening overseas sales mainly in EUand ChinaIncrease in amortization of goodwill ( 1,469 Mil. Yen) Ordinary income 14,458 Mil. Yen (YoY 9.6%) Net income attributable to parent company shareholders:10,498 Mil. Yen (YoY 5.1%)(Unit : JPY)US 108.00 EURO 130.00FYE June 2022(Plan)CNY16.50 BAHT 3.50US 106.58 EURO 127.06FYE June 2021CNY16.12 BAHT 3.45Effect of exchange rate on operating income (Main currency)US ( 1 yen influence) : approx. 143 Mil. Yen IncreaseEURO ( 1 yen influence) : approx. 86 Mil. Yen IncreaseCNY ( 1 yen influence) : approx. 660 Mil. Yen IncreaseBAHT( 0.1 yen influence) : approx. 346 Mil. Yen Decrease
23All Rights Reserved.Copyright 2021 ASAHI INTECC CO.,LTD.Earnings Forecast for FYE June 2022FYE June 2021(Results)FYE June 2022(Plan)YoYAmount(Mil. Yen)Ratio(%)Amount(Mil. Yen)Ratio(%)Changes(Mil. Yen)Changes(%)Revenue61,507100.075,296100.0 13,789 22.4Gross profit41,46867.449,98666.4 8,517 20.5Operating incomebeforeamortization ofgoodwill12,94421.016,12821.4 3,184 24.6Operating income12,79520.814,51019.3 1,715 13.4Ordinary income13,19621.514,45819.2 1,262 9.6Net incomeattributable toparent companyshareholders9,98416.210,49813.9 513 5.138.25yen－38.65yen 0.40yen 1.0EPS※－※：The EPS for the fiscal year ending June 2022 is calculated based on the number of issued shares of 271,625,722 (excluding treasury stock) inconsideration of the exercise of stock acquisition rights.
24All Rights Reserved.Copyright 2021 ASAHI INTECC CO.,LTD.Earnings Forecast for by Segment【 Revenue 】( Mil. Yen )【 Operating Income 】( Mil. Yen )Beforeamortizationof 5,2315,00020,0000-4,254-4,453-4,453FYE June 2021FYE June 2022FYE June 2022（Plan）（Plan）0FYE June 2021（Results）FYE June 2022（Plan）-5,000（Results）
25All Rights Reserved.Copyright 2021 ASAHI INTECC CO.,LTD.Attribution Analysis of Operating Income(Exchange Rate Fluctuations Included)Positive effect ofincreased revenue( Mil. Yen )-637Negative effectof increasedgross profit rate20,000 9,154Negative effectof increased expensesother thanR&D expenses-5,422Negative effectof increasedR&D expenses-1,37915,00014,51012,795Increase in SGA -6,80210,0005,000FYE June 2022 Exchange(Plan) : US 108.00 EURO 130.00 CNY 16.50 BAHT 3.50FYE June 2021 Exchange: US 106.58 EURO 127.06 CNY 16.12 BAHT 3.450FYE June 2021Operating Income(Results)FYE June 2022Operating Income(Plan)
26All Rights Reserved.Copyright 2021 ASAHI INTECC CO.,LTD.Attribution Analysis of Operating Income(Exchange Rate Fluctuations Excluded)Negative effectNegative effectPositive effect ofof increased of increased expensesother thanincreased revenue gross profit rateR&D expenses( Mil. Yen )-78320,000 8,474Currencyexchange rateinfluence15,00012,795-5,259Negative effectof increasedR&D expenses-1,35914,510 643Increase in SGA -6,61910,0005,000FYE June 2022 Exchange(Plan) : US 108.00 EURO 130.00 CNY 16.50 BAHT 3.50FYE June 2021 Exchange: US 106.58 EURO 127.06 CNY 16.12 BAHT 3.450FYE June 2021Operating Income(Results)FYE June 2022Operating Income(Plan)
27All Rights Reserved.Copyright 2021 ASAHI INTECC CO.,LTD.Results and Plan for Equipment InstallationExpansion of development bases and overseas factory bases to increaseproduction in the future( Mil. Yen )Main investment matterFYE June 2019 FYE June 2020 FYE June 2021 FYE June 2022(Results)(Results)(Results)(Plan)Construction of New Building at Seto factory30,000Establishment of Tohoku R&D Center2,154157812942492,038Expansion of Osaka R&D Center3,710Land and Building (New Thai Medical factory)25,000Expansion of Thai Medical factory20,0001,478Construction of First Cebu Medical factory302Construction of Second Cebu Medical factory478Land and Building(New Cebu Device factory )15,00010,000EquipmentInvestmentIntroduction of core information system(SAP)(Start operation in July reciation andAmortization1,574FYE June20172,886FYE June20183,460FYE June2019（Results）4,198FYE June20204,819FYE June2021FYE June2022（Plan）
28All Rights Reserved.Copyright 2021 ASAHI INTECC CO.,LTD.R&D ExpensesIncrease in R&D expenses for new projects(Mil. Yen)14.0%R&D Expenses12,00012.2%Ratio of Revenue to R&D 004.0%2,0002.0%00.0%FYE June2017FYE June2018FYE June2019FYE June2020FYE June2021FYE June2022Plan
29All Rights Reserved.Copyright 2021 ASAHI INTECC CO.,LTD.Caution Regarding Information PresentedAll forward looking statements contained herein, including revenue forecasts, outlooks,and strategic plans, are based on the best currently available data; however, risk anduncertainty are involved in these statements. Please note that actual results may differ greatlyfrom plans presented here.【 IR contact 】Asahi Intecc Co., Ltd. corporate strategic officeTEL 0561-48-5551URL http://www.asahi-intecc.co.jp/en/
promotion of direct sales Chinese: Increase significantly due to strengthening sales promotion activities Europe/Middle East: Western Europe increased while Eastern Europe/Russia and Middle East decreased Western Europe: Increase due to the promotion of direct sales in France and Germany, etc. Middle East: Impact of COVID-19, etc.
1.8-1.9 Is the library now reporting on a different fiscal year than it reported on in the previous Annual Report? – If the library's fiscal year has changed please answer this question accordingly and contact your library system. 1.11-1.12 Beginning Local Fiscal Year and Ending Local Fiscal Year-Beginning Local Fiscal Year (operating year) and Ending Local Fiscal Year (operating year) –
Fiscal Year (operating year) and Ending Local Fiscal Year (operating year) – Enter the beginning and ending dates of the library's local fiscal year, even if they are the same as the fiscal reporting year indicated in Questions 1.6 and 1.7. (For example, a school district library's local fiscal year may be July 1 – June 30, but the library .
Chapter 15: Fiscal Policy The Effects of Fiscal Policy on Real GDP and the Price Level Expansionary and Contractionary Fiscal Policy Figure 15-5. Fiscal Policy. Explain how fiscal policy affects aggregate demand and how the government can use fiscal policy to stabilize the economy. In
Project Total 580 2,000 3,000 5,580. Adopted CIP Form C 5. PARKS AND RECREATION FACILITIES - Summary of Funds 2018-2022 CAPITAL IMPROVEMENT PLAN ( Thousands) . F-000850 Sagemont Park CC Gym Floor Fiscal Year Fiscal Year Fiscal Year Fiscal Year Fiscal Year F0008
The Juvenile Justice Department turnover rate of 31.1 percent in fiscal year 2017 was an increase from its turnover rate of 29.2 percent in fiscal year 2016. That was followed by the Department of Criminal Justice, whose turnover rate of 23.6 percent in fiscal year 2017 was an increase from 19.5 percent in fiscal year 2016.
－ 1 － Summary of Financial Results for the Fiscal Year ended March 31, 2009 May 13, 2009 (Figures less than one million yen are omitted) 1. Consolidated Business Results for the Fiscal Y
)--Dollar General Corporation (NYSE: DG) today reported financial results. for its fiscal year 2021 fourth quarter (13 weeks) and fiscal year (52 weeks) ended January 28, 2022. Fourth Quarter Net Sales Increased 2.8%; Fiscal Year Net Sales Increased 1.4% Fourth Quarter Same-Store Sales Decreased 1.4%; Increased 11.3% on a two-year stack basis
Oracle Investor Relations Oracle Corporate Communications 1.650.607.0349 1.212.508.7935 ken.bond@oracle.com deborah.hellinger@oracle.com Oracle Announces Fiscal 2021 Fourth Quarter and Fiscal Full Year Financial Results Q4 FY21 Earnings Per Share: GAAP EPS up 39% to 1.37, Non-GAAP EPS up 29% to 1.54 .
